Pyrazinamide pharmacokinetics and efficacy in adults and children

Tuberculosis

Volumn 92, Issue 1, 2012, Pages 1-8

  Donald, P R ^a   Maritz, J S ^a   Diacon, A H ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antituberculosis chemotherapy; Children; Dosage; Pharmacokinetics; Pyrazinamide

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIUM EXAMINATION; BLOOD CULTURE; BODY WEIGHT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; PHARMACOKINETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PRACTICE GUIDELINES AS TOPIC; PYRAZINAMIDE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84856466116     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2011.05.006     Document Type: Review

References (82)

1. M.V. Chorine Action del'amide nicotinique sur le bacilles du genre Mycobacterium Comp rond de l'Acad Des Sci 220 1945 150 151
2. D. McKenzie, L. Malone, S. Kushner, J.J. Oleson, and Y. SubbaRow The effect of nicotinic acid amide on experimental tuberculosis of white mice J Lab Clin Med 33 1948 1249 1253
3. S. Kushner, H. Dalalian, J.L. Sanjurjo, F.L. Bach, S.R. Safir, V.K. Smith, and J.H. Williams Experimental chemotherapy of tuberculosis. II The synthesis of pyraxiamides and related compounds J Am Chem Soc 74 1952 3617 3620
4. M. Solotorovsky, F.J. Gregory, E.J. Ironson, E.J. Bugie, R.C. O'Neil, and K. Pfister Pyrazinoic acid amide - an agent active against experimental murine tuberculosis (199447) Proc Soc Exp Biol Med 79 1952 563 565
5. O. Dalmer, and E. Walter VerFahren zur Herstellung von Abkömmelingen der Pyrazinomonocarbonsäure 1936 Germany patent 632,257
6. R.L. Yeager, W.G.C. Munroe, and F.I. Dessau Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis Am Rev Tuberc 65 1952 523 534
7. W. McDermott, L. Ormond, C. Muschenheim, K. Deuschle, R.M. McCune, and R. Tompsett Pyrazinamide-isoniazid in tuberculosis Am Rev Tuberc 69 1954 319 333
8. C. Muschenheim, W. McDermott, R. McCune, K. Deuschle, L. Ormond, and R. Tompsett Pyrazinamide-isoniazid in tuberculosis. II Results in 58 patients with pulmonary lesions one year after the start of therapy Am Rev Tuberc 70 1954 743 747
9. C. Muschenheim, A. Organick, R.M. McCune, J. Batten, K. Deuschle, R. Tompsett, and W. McDermott Pyrazinamide-isoniazid in tuberculosis. III Observations with reduced dosage of pyrazinamide Am Rev Tuberc Respir Dis 72 1955 851 855
10. S.T. Allison Pyrazinamide-isoniazid in low dosage in the treatment of Pulmonary Tuberculosis Am Rev Tuberc Pulmon Dis 74 1956 400 405
11. East African/British Medical Research Councils Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report Tubercle 67 1986 5 15
12. East African/British Medical Research Councils Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis Lancet 1 1972 1079 1085
13. East African/British Medical Research Councils Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis Lancet 2 1974 237 240
14. East African/British Medical Research Councils Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis Tubercle 64 1983 153 166
15. Hong Kong Chest Service/British Medical Research Council Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide Am Rev Respir Dis 143 1991 700 706
16. D.A. Mitchison, and A.J. Nunn Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis Am Rev Respir Dis 133 1986 423 430 (Pubitemid 16126276)
17. East African/British Medical Research Councils A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis Tubercle 50 1969 81 115
18. M. Zierski, and A. Zachara Late results in retreatment of patients with pulmonary tuberculosis Tubercle 51 1971 172 177
19. Singapore Tuberculosis Service/British Medical Research Council Clinical trial of six-month and four-month regimens of chemotherapy in the reatment of pulmonary tuberculosis Am Rev Respir Dis 119 1979 579 586
20. East African/British Medical Research Councils Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Final report Tubercle 67 1986 5 15
21. Y.P. Hong, S.C. Kim, S.C. Chang, S.J. Kim, B.W. Jin, and C.D. Park Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions Tubercle 69 1988 241 253 (Pubitemid 19009801)
22. D.J. Girling The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis Tubercle 65 1984 1 4 (Pubitemid 14155785)
23. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes. WHO/CDS/TB/2003.313.
24. A. Jindani, V.R. Aber, E.A. Edwards, and D.A. Mitchison The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am Rev Respir Dis 121 1980 939 949 (Pubitemid 10118376)
25. F.J.H. Botha, F.A. Sirgel, D.P. Parkin, B.W. Van de Wal, P.R. Donald, and D.A. Mitchison Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis S Afr Med J 86 1996 155 158 (Pubitemid 26098387)
26. C.A. Peloquin Therapeutic drug monitoring: principles and applications in mycobacterial infections Drug Ther 22 1992 31 36
27. D.C. Perlman, Y. Segal, S. Rosenkranz, P.M. Rainey, C.A. Peloquin, R.P. Remmel, N. Salomon, R. Hafner, C.A. Peloquin AIDS Clinical Trials Group 309 Team The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis Clin Infect Dis 38 2004 556 5564
28. S. Chideya, C.A. Winston, C.A. Peloquin, W.Z. Bradford, P.C. Hopewell, C.D. Wells, A.L. Reingold, T.A. Kenyon, T.L. Moeti, and J.W. Tappero Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana Clin Infect Dis 48 2009 1685 1694
29. M. Salfinger, and L.B. Heifets Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method Antimicrob Agents Chemother 32 1988 1002 1004
30. I. Sánchez -Albisua, L. Vidal, G. Joya-Verde, F. Del Castillo, M.I. De José, and J. Garcia-Hortelano Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children Pediatr Infect Dis J 16 1997 760 763 (Pubitemid 27364787)
31. D. Corrrigan, and J. Paton Hepatic enzyme abnormalities in children on triple therapy for tuberculosis Pediatr Pulmon 27 1999 37 42 (Pubitemid 29063800)
32. G.A. Ellard Absorption, metabolism and excretion of pyrazinamide in man Tubercle 50 1969 144 158
33. C. La Croix, T.P. Hoang, J. Nouveau, C. Guyonnaud, G. Laine, H. Duwoos, and O. Lafont Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects Eur J Clin Pharmacol 36 1989 395 400 (Pubitemid 19140044)
34. C.A. Peloquin, A.E. Bulpitt, G.S. Jaresko, R.W. Jelliffe, G.T. James, and D.E. Nix Pharmacokinetics of pyrazinamide under fasting conditions with food and with antacids Pharmacother 18 1998 1205 1211 (Pubitemid 28533871)
35. V. Roy, U. Tekur, and K. Chopra Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis Int J Tuberc Lung Dis 3 1999 133 137 (Pubitemid 29151816)
36. J.J. Wilkins, G. Langdon, H. McIlleron, G. Pillai, P.J. Smith, and U.S.H. Simonsson Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients Eur J Clin Pharmacol 62 2006 727 735 (Pubitemid 44289503)
37. G. Acocella, A. Nonis, G. Perna, E. Patane, G. Gialdroni-Grassi, and C. Grassi Comparative bioavailability of isoniazid, rifampin and pyrazinamide administered in free combination and in fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month daily administration study Am Rev Respir Dis 138 1988 886 890
38. S.R. Bareggi, R. Ceruti, R. Pirola, R. Riva, and M. Cisternino Clinical pharmacokinetics and metabolism of pyrazinamide in healthy volunteers Arzneim-Forsch 37 1987 849 854 (Pubitemid 17094393)
39. G. Acocella, M. Luisetti, G.G. Grassi, V. Peona, E. Pozzi, and C. Grassi Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed triple formulation) in intermittent antituberculous chemotherapy Monaldi Arch Chest Dis 48 1993 205 209 (Pubitemid 23288180)
40. G. Acocella, A. Nonis, G. Gialdroni-Grassi, and C. Grassi Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in fixed triple formulation designed for daily use in antituberculosis chemotherapy Am Rev Respir Dis 138 1988 882 885
41. C. La Croix, C. Guyonnaud, M. Chaou, H. Duwoos, and O. Lafont Interaction between allopurinol and pyrazinamide Eur Resp J 1 1988 807 811
42. R. Panchagnula, P. Sancheti, S. Rungta, S. Agrawal, and C.L. Kaul Evaluation of bioequivalence of isoniazid and pyrazimamide in three and four drugs fixed dose combinations using WHO simplified protocol Pharmacol Res 48 2003 383 387 (Pubitemid 36945337)
43. S. Agrawal, I. Singh, K.J. Kaur, S.R. Bhade, C.L. Kaul, and R. Panchagnula Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels Int J Pharmac 276 2004 41 49 (Pubitemid 38542986)
44. B. Taylor, and P.J. Smith Does AIDS impair the absorption of antituberculosis agents Int J Tuberc Lung Dis 2 1998 670 675
45. J.W. Tappero, W.Z. Bradford, T.B. Agerton, P. Hopewell, A.L. Reingold, S. Lockman, A. Oyewo, E.A. Talbot, T.A. Kenyon, T.L. Moeti, H.J. Moffat, and C.A. Peloquin Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana Clin Infect Dis 41 2005 461 469 (Pubitemid 41099637)
46. H. McIlleron, P. Wash, A. Burger, J. Norman, P.I. Folb, and P. Smith Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients Antimicrob Agents Chemother 50 2006 1170 1177
47. G.A. Ellard, D.R. Ellard, B.W. Allen, D.J. Girling, A.J. Nunn, S.K. Teo, T.H. Tan, H.K. Ng, and S.L. Chan The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis Am Rev Respir Dis 133 1986 1076 1080 (Pubitemid 16090016)
48. M. Zhu, J.R. Starke, W.J. Burman, P. Steiner, J.J. Stambaugh, D. Ashkin, A.E. Bulpitt, S.E. Berning, and C.A. Peloquin Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis Pharmacother 22 2002 686 695 (Pubitemid 34596476)
49. J. Sahai, K. Gallicano, L. Swick, S. Tailor, G. Garber, I. Seguin, L. Oliveras, S. Walkor, A. Bachlin, and D.W. Cameron Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection Ann Intern Med 127 1997 289 293 (Pubitemid 27352050)
50. J.E. Conte, J.A. Golden, S. Duncan, E. McKenna, and E. Zurlinden Intrapulmonary concentrations of pyrazinamide Antmicrob Agents Chemother 43 1999 1329 1333 (Pubitemid 29259320)
51. K. Magdorf Intensiv-Anfangsbehandelung bei der Kindertuberkulose unter besonderer Berücksichtigung des pyrazinamids Intensivbehandelung 12 1987 99 102
52. S. Thee, A. Detjen, U. Wahn, and K. Magdorf Pyrazinamide serum levels in childhood tuberculosis Int J Tuberc Lung Dis 12 2008 1099 1101
53. S.M. Graham, D.J. Bell, S. Nyirongo, R. Hartkoorn, S.A. Ward, and E.M. Molyneux Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status and human immunodeficiency virus infection Antimicrob Agents Chemother 50 2006 407 413 (Pubitemid 43190946)
54. P. Gupta, V. Roy, G.R. Sethi, and T.K. Mishra Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses Brit J Clin Pharmacol 65 2007 423 427 (Pubitemid 351316921)
55. D.S. Arya, S.K. Ojha, O.P. Semwal, and M. Nandave Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs Ind J Med Res 128 2008 611 615
56. H. McIlleron, M. Willemse, H.S. Schaaf, P.J. Smith, and P.R. Donald Plasma concentrations of pyrazinamide in young children with tuberculosis Pediatr Infect Dis 30 2011 262 265
57. S.H. Choudhri, M. Hawken, S. Gathua, G.O. Minyiri, W. Watkins, J. Sahai, D.S. Sitar, F.Y. Aoki, and R. Long Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhea Clin Infect Dis 25 1997 104 111 (Pubitemid 27293083)
58. M.H.D. Smith What about short course and intermittent chemotherapy for tuberculosis in children Pediatr Infect Dis J 1 1982 298 303 (Pubitemid 13136507)
59. R.F. Jacobs, and R.S. Abernathy The treatment of tuberculosis in children Pediatr Infect Dis 4 1985 513 517 (Pubitemid 15019918)
60. American Thoracic Society Treatment of tuberculosis and tuberculosis infection in adults and children Am Rev Respir Dis 134 1986 355 363
61. O.R.P. Beltran, F. Pelosi, and H. Budani The treatment of child tuberculosis with isoniazid (H), rifampicin (R) and pyrazinamide (Z) Bull Int Union Tuberc 61 17 1986 A020
62. A. Rakhit, P.G. Khandelwal, S.K. Mukherjee, and A.K. Dey Intensive short-course chemotherapy in pulmonary tuberculosis Indian J Pediatr 53 1986 243 248
63. J. Biddulph, D. Mokela, and S. Sharma Compliance of children with tuberculosis treated by short-course intensive chemotherapy Papua New Guinea Med J 30 1987 159 164
64. J. Biddulph, V. Kokoha, and S. Sharma Short course chemotherapy in childhood tuberculosis J Trop Pediatr 34 1988 20 23 (Pubitemid 18072285)
65. D.E. Snider, H.L. Rieder, D. Combs, A.B. Bloch, C.H. Hayden, and M.H.D. Smith Tuberculosis in children Pediatr Infect Dis J 7 1988 271 278
66. J.R. Starke, and K.T. Taylor-Watts Tuberculosis in the pediatric population of Houston, Texas Pediatrics 84 1989 28 35 (Pubitemid 19168034)
67. L. Kumar, R. Dhand, P.D. Singhi, K.L.N. Rao, and S. Katariy A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis Pediatr Infect Dis J 9 1990 802 806 (Pubitemid 20385445)
68. International Union Against Tuberculosis and Lung Disease Scientific committee. Tuberculosis in children. Guidelines for diagnosis, prevention and treatment Bull Int Union Tuberc Lung Dis 66 1991 61 67
69. J.R. Starke, R.F. Jacobs, and J. Jereb Resurgence of tuberculosis in children J Pediatr 120 1992 839 855
70. World Health Organization Treatment of tuberculosis. Guidelines for national programmes 1993 WHO Geneva
71. American Thoracic Society Treatment of tuberculosis and tuberculosis infection in adults and children Clin Infect Dis 21 1995 9 27
72. J.R. Starke, and A.G. Correa Management of mycobacterial infection and disease in children Pediatr Infect Dis 14 1995 455 470
73. British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax 53 1998 536 548
74. P. Ramachandran, A.S. Kripasankar, and M. Duraipandian Short course chemotherapy for pulmonary tuberculosis in children Ind J Tuberc 45 1998 83 87
75. American Thoracic Society/Centers for disease Control and Prevention/Infectious Diseases Society of America Treatment of tuberculosis Am J Respir Crit Care Med 167 2003 603 662
76. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO, Geneva: WHO/HTM/2006.371.
77. The National Tuberculosis Programme of Mexico. Practical Guide for the management of tuberculosis in Infants, children and Adolescents. ISBN 970-721-334-5: 81-97.
78. D.J. Girling The hepatic toxicity of antituberculosis rgimens containing isoniazid, rifampicin and pyrazinamide Tubercle 59 1978 13 32 (Pubitemid 8283038)
79. M. Zierski Pharmakologie, toxikologie und klinische Anwendung von Pyrazinamid Prax Pneumol 35 1981 1075 1105 (Pubitemid 12251044)
80. J.G. Pasipanodya, and T. Gumbo Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used Antimicrob Agents Chemother 54 2010 2847 2854
81. T. Gumbo, C.S.W. Siyambalapitiyage, C. Meek, and R. Leff Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs Antimicrob Agents Chemother 53 2009 3197 3204
82. World Health Organization. Rapid advice. Treatment of tuberculosis in children.WHO/HTM/TB/2010.13.